Hugging Face's logo

Spaces:
ferferefer
/
preserflo_slides
Running

App Files Community
preserflo_slides / index.html
ferferefer's picture
ferferefer
Upload index.html
f688d5f verified
raw
history blame
23.3 kB
 <!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Preserflo™ MicroShunt Presentation</title>
<!-- Tailwind CSS -->
<script src="https://cdn.tailwindcss.com"></script>
<!-- reveal.js -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.css">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/theme/sky.min.css" id="theme">
<!-- Font Awesome Icons -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
<style>
/* Custom Styles for Professional Look */
.reveal .slides section {
text-align: left; /* Default text alignment */
display: flex !important;
flex-direction: column;
justify-content: center; /* Center content vertically */
align-items: center; /* Center content horizontally */
min-height: 700px; /* Consistent slide height */
padding: 40px; /* Padding around slide content */
box-sizing: border-box;
}
.reveal .slide-content {
display: flex;
align-items: center; /* Vertically align items in the flex container */
justify-content: space-between; /* Space out text and visual content */
width: 100%; /* Full width within padding */
max-width: 1100px; /* Max width for content */
margin: auto; /* Center the content container */
}
.reveal .slide-content-vertical { /* For layouts where visual is above/below text */
flex-direction: column;
text-align: center;
}
.reveal .text-content {
flex: 1; /* Allow text content to take available space */
padding-right: 30px; /* Space between text and visual */
max-width: 60%; /* Limit text width for readability */
}
.reveal .text-content-full { /* For slides primarily text */
flex: 1;
width: 100%;
max-width: 900px; /* Wider max-width for text-heavy slides */
}
.reveal .visual-content {
flex-shrink: 0; /* Prevent visual content from shrinking */
width: 35%; /* Adjust visual content width */
text-align: center; /* Center images/icons */
}
.reveal .visual-content-full { /* For title slide visual */
width: auto;
margin-top: 2rem;
}
.reveal .visual-content i { /* Icon styling */
font-size: 7rem; /* Standard icon size */
color: #0ea5e9; /* Tailwind sky-500 */
margin-bottom: 1rem;
}
.reveal img.slide-image {
max-width: 100%;
max-height: 350px; /* Limit image height */
object-fit: contain; /* Ensure image scales nicely */
border-radius: 8px; /* Slightly rounded corners */
box-shadow: 0 4px 8px rgba(0,0,0,0.1); /* Subtle shadow */
}
.reveal h1 {
color: #ffffff; /* White for title slide */
font-size: 3.5em;
font-weight: bold;
margin-bottom: 0.5em;
}
.reveal h2 {
color: #0284c7; /* Tailwind sky-600 */
font-size: 2.5em;
font-weight: bold;
margin-bottom: 1em;
text-align: center;
width: 100%;
}
.reveal h3 {
color: #0369a1; /* Tailwind sky-700 */
font-size: 1.6em;
font-weight: bold;
margin-bottom: 0.8em;
}
.reveal h4 {
font-size: 1.2em;
color: #075985; /* Tailwind sky-800 */
font-weight: bold;
margin-bottom: 0.5em;
}
.reveal ul {
list-style: none;
padding-left: 0;
}
.reveal ul li {
font-size: 1.0em;
margin-bottom: 0.7em;
padding-left: 2em;
position: relative;
line-height: 1.4;
}
.reveal ul li::before {
content: "\f00c"; /* Font Awesome check icon */
font-family: 'Font Awesome 6 Free';
font-weight: 900;
color: #34d399; /* Tailwind emerald-400 */
position: absolute;
left: 0;
top: 4px;
font-size: 0.9em;
}
.reveal p {
font-size: 1.05em;
line-height: 1.5;
margin-bottom: 1em;
}
.reveal .citation {
font-size: 0.65em;
color: #6b7280; /* Tailwind gray-500 */
margin-top: 15px;
display: block;
text-align: right;
}
.reveal .slide-background-content { /* Default slide background */
background-color: #f0f9ff; /* Tailwind sky-50 */
}
/* Specific Slide Backgrounds */
.reveal section[data-background-color="#0ea5e9"] h1,
.reveal section[data-background-color="#0ea5e9"] p {
color: white;
}
.reveal section[data-background-color="#0ea5e9"] i {
color: white;
}
.comparison-grid {
display: grid;
grid-template-columns: 1fr 1fr;
gap: 20px;
width: 100%;
}
.comparison-grid h4 {
text-align: center;
margin-bottom: 1em;
}
.comparison-grid ul li::before {
top: 6px; /* Adjust icon position slightly */
}
</style>
</head>
<body>
<div class="reveal">
<div class="slides">
<!-- Slide 1: Title -->
<section data-background-color="#0ea5e9">
<div class="slide-content-vertical">
<h1>The Preserflo™ MicroShunt</h1>
<p class="text-2xl font-light">A Modern Surgical Solution for Glaucoma Management</p>
<div class="visual-content-full">
<i class="fas fa-eye text-7xl"></i>
</div>
</div>
</section>
<!-- Slide 2: What is Glaucoma? -->
<section class="slide-background-content">
<h2>Understanding Glaucoma</h2>
<div class="slide-content">
<div class="text-content">
<h3>The Challenge of IOP</h3>
<p>Glaucoma is a group of eye diseases often characterized by elevated Intraocular Pressure (IOP). [3, 6] This pressure rises when the eye's natural fluid (aqueous humor) doesn't drain properly due to blockage. [3, 8]</p>
<p>Sustained high IOP damages the optic nerve, responsible for sending visual information to the brain, which can lead to permanent vision loss. [2, 3, 6] The core goal of glaucoma treatment is effectively lowering IOP to preserve sight. [1, 7]</p>
<span class="citation">Sources: [1], [2], [3], [6], [7], [8]</span>
</div>
<div class="visual-content">
<i class="fas fa-tachometer-alt-fast"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram illustrating increased IOP and potential optic nerve damage]</p>
</div>
</div>
</section>
<!-- Slide 3: What is Preserflo? -->
<section class="slide-background-content">
<h2>Introducing Preserflo™ MicroShunt</h2>
<div class="slide-content">
<div class="text-content">
<h3>Device Overview</h3>
<p>The Preserflo™ MicroShunt is a tiny, soft, flexible tube, about 8-8.5mm long, designed specifically for glaucoma surgery. [2, 3, 7, 21] Its primary function is to safely lower eye pressure. [1, 2, 7]</p>
<p>It's crafted from SIBS (poly(styrene-block-isobutylene-block-styrene)), a highly biocompatible and inert material also used in coronary stents. [1, 2, 7, 24] This minimizes inflammation and the risk of rejection or degradation. [2, 3, 7, 23]</p>
<p>Features include stabilizing fins and a precise lumen diameter (70µm internal) designed to control fluid outflow. [1, 8, 13, 22] It is non-metallic and MRI/CT safe. [2, 3, 7]</p>
<span class="citation">Sources: [1], [2], [3], [7], [8], [13], [21], [22], [23], [24]</span>
</div>
<div class="visual-content">
<!-- Placeholder for actual image -->
<img src="https://via.placeholder.com/300x200.png?text=Preserflo+MicroShunt+Device" alt="Preserflo MicroShunt Device" class="slide-image">
<p class="mt-2 text-sm text-gray-600">[Placeholder: Actual image of the Preserflo MicroShunt]</p>
</div>
</div>
</section>
<!-- Slide 4: How it Works -->
<section class="slide-background-content">
<h2>Mechanism of Action</h2>
<div class="slide-content">
<div class="visual-content">
<!-- Placeholder for actual image/diagram -->
<img src="https://via.placeholder.com/300x300.png?text=Shunt+Placement+Diagram" alt="Diagram showing Preserflo placement and bleb formation" class="slide-image">
<p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram showing shunt placement and fluid flow to bleb]</p>
</div>
<div class="text-content pl-8">
<h3>Creating a New Pathway</h3>
<p>The MicroShunt acts as a bypass for the eye's natural, obstructed drainage system. [3, 6, 7, 13]</p>
<p>Implanted via an 'ab externo' approach, one end sits in the anterior chamber, accessing the excess aqueous humor. [1, 4, 6, 8] The other end channels this fluid out of the eye, directing it into the subconjunctival/sub-Tenon space. [2, 4, 8, 23]</p>
<p>This drained fluid forms a small, low-profile reservoir called a 'bleb' under the upper eyelid, where it is safely absorbed by surrounding tissues into the bloodstream, thus reducing IOP. [2, 3, 5, 7]</p>
<span class="citation">Sources: [1], [2], [3], [4], [5], [6], [7], [8], [13], [23]</span>
</div>
</div>
</section>
<!-- Slide 5: Indications -->
<section class="slide-background-content">
<h2>Who is a Candidate for Preserflo?</h2>
<div class="slide-content">
<div class="text-content">
<h3>Patient Suitability</h3>
<ul>
<li>Primarily indicated for Primary Open-Angle Glaucoma (POAG), including subtypes like pseudoexfoliation and pigmentary glaucoma. [1, 11, 18]</li>
<li>Patients whose IOP is not adequately controlled with maximal tolerated medications or laser therapy. [2, 7, 8, 11]</li>
<li>Individuals experiencing glaucoma progression that necessitates surgical intervention. [6, 8, 11]</li>
<li>Those who have difficulty with adherence to, or intolerance of, eye drop regimens. [7, 11]</li>
<li>May be considered for moderate-to-advanced glaucoma stages. [3, 10]</li>
</ul>
<p>Not suitable for angle-closure glaucoma, active infection, or severe dry eye. [1, 8, 13]</p>
<span class="citation">Sources: [1], [2], [3], [6], [7], [8], [10], [11], [13], [18]</span>
</div>
<div class="visual-content">
<i class="fas fa-user-check"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Image representing patient consultation or eye exam]</p>
</div>
</div>
</section>
<!-- Slide 6: The Procedure -->
<section class="slide-background-content">
<h2>The Implantation Procedure</h2>
<div class="slide-content">
<div class="visual-content">
<i class="fas fa-user-md"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Image or simple graphic of surgical setting/instruments]</p>
</div>
<div class="text-content pl-8">
<h3>Surgical Steps</h3>
<ul>
<li>Typically performed as an outpatient (day surgery) procedure. [2, 4, 6, 13]</li>
<li>Surgery duration is often around 30-45 minutes. [2, 21, 26]</li>
<li>Anesthesia options include local (injection or drops) or general anesthesia. [1, 2, 19]</li>
<li>Utilizes an 'ab externo' technique, familiar to glaucoma surgeons. [1, 22, 23]</li>
<li>Involves a conjunctival incision and careful dissection. [1, 2]</li>
<li>Mitomycin-C (MMC), an anti-scarring agent, is applied to enhance long-term success. [1, 2, 21, 17]</li>
<li>The MicroShunt is inserted, and the conjunctiva is closed, often with dissolvable stitches. [2, 3]</li>
</ul>
<span class="citation">Sources: [1], [2], [3], [4], [6], [13], [17], [19], [21], [22], [23], [26]</span>
</div>
</div>
</section>
<!-- Slide 7: Benefits -->
<section class="slide-background-content">
<h2>Benefits of Preserflo™ MicroShunt</h2>
<div class="slide-content">
<div class="text-content">
<h3>Key Advantages</h3>
<ul>
<li><strong>Significant IOP Lowering:</strong> Proven to effectively reduce eye pressure, with studies showing sustained results. [1, 4, 7, 20, 26]</li>
<li><strong>Less Dependence on Drops:</strong> Substantially reduces or eliminates the need for daily glaucoma medications for many patients. [2, 3, 6, 7, 8, 13, 16, 17, 20]</li>
<li><strong>Less Invasive Nature:</strong> Compared to trabeculectomy, the procedure is generally considered less invasive. [4, 6, 12, 13, 19, 23, 26]</li>
<li><strong>Favorable Safety Profile:</strong> Designed to minimize risks, with studies indicating lower rates of certain complications like hypotony vs. trabeculectomy. [4, 8, 9, 13, 19, 22, 26, 29]</li>
<li><strong>Potentially Faster Recovery:</strong> Patients may experience quicker visual recovery and return to normal activities. [6, 19, 22, 26]</li>
<li><strong>Predictability:</strong> Aims for more predictable IOP outcomes compared to trabeculectomy. [22]</li>
</ul>
<span class="citation">Sources: [1-4, 6-9, 12, 13, 16, 17, 19, 20, 22, 23, 26, 29]</span>
</div>
<div class="visual-content">
<i class="fas fa-shield-check"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Icon or graphic representing benefits/improvement]</p>
</div>
</div>
</section>
<!-- Slide 8: Preserflo vs. Trabeculectomy -->
<section class="slide-background-content">
<h2>Preserflo vs. Trabeculectomy: Comparison</h2>
<div class="text-content-full">
<h3>Why Preserflo Might Be Preferred</h3>
<div class="comparison-grid mt-4">
<div>
<h4 class="text-sky-700">Preserflo MicroShunt</h4>
<ul>
<li>Standardized device & procedure [1, 22]</li>
<li>Less invasive surgical technique [19, 23, 26]</li>
<li>Significantly lower risk of hypotony [5, 25, 28, 29]</li>
<li>Potentially fewer complications overall [5, 13, 26]</li>
<li>Fewer postoperative interventions (needling, etc.) in some studies [12, 23, 25]</li>
<li>Faster visual recovery suggested [19, 22, 26]</li>
<li>Better visual field preservation reported [5, 29]</li>
<li>More posterior bleb formation [15, 23]</li>
</ul>
</div>
<div>
<h4 class="text-sky-700">Trabeculectomy</h4>
<ul>
<li>Long-established "gold standard" [12, 23]</li>
<li>Requires manual scleral flap creation [14, 22]</li>
<li>Higher incidence of early hypotony [25, 28, 29]</li>
<li>Can have more early/late complications [5]</li>
<li>Often needs more intensive post-op management [12, 23, 25]</li>
<li>May achieve slightly lower IOP in some studies [14, 22, 29]</li>
<li>More anterior bleb [15, 23]</li>
</ul>
</div>
</div>
<p class="mt-6 text-center">Preserflo offers a balance of effective IOP control with an improved safety profile and potentially simpler recovery, making it an attractive alternative, especially where hypotony is a concern. [12, 19, 22, 25, 29]</p>
<span class="citation">Sources: [1, 5, 12-15, 19, 22, 23, 25, 26, 28, 29]</span>
</div>
</section>
<!-- Slide 9: Safety & Considerations -->
<section class="slide-background-content">
<h2>Safety & Important Considerations</h2>
<div class="slide-content">
<div class="text-content">
<h3>Potential Risks</h3>
<p>While designed for safety, potential surgical risks include:</p>
<ul>
<li><strong>IOP Fluctuations:</strong> Pressure may become too low (hypotony, often transient) or remain too high (hypertension), potentially requiring management. [1, 2, 3, 9, 13, 20, 21, 28]</li>
<li><strong>Bleeding (Hyphema):</strong> Usually minimal and resolves spontaneously; severe bleeding is rare. [2, 7, 9, 21]</li>
<li><strong>Infection (Endophthalmitis):</strong> A rare but serious lifelong risk associated with filtering blebs. [2, 3, 9, 13]</li>
<li><strong>Need for Re-intervention:</strong> Scarring or blockage may necessitate procedures like bleb needling or surgical revision. [1, 2, 3, 16, 20, 28, 29]</li>
<li><strong>Other Potential Issues:</strong> Transient blurred vision, shallow anterior chamber, choroidal effusion/detachment, cataract progression, rare shunt exposure or migration. [1, 2, 3, 9, 20]</li>
</ul>
<p>Regular post-operative monitoring is crucial for optimal outcomes. [2, 3, 5]</p>
<span class="citation">Sources: [1-3, 5, 7, 9, 13, 16, 20, 21, 28, 29]</span>
</div>
<div class="visual-content">
<i class="fas fa-exclamation-triangle text-yellow-500"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Icon representing caution or safety check]</p>
</div>
</div>
</section>
<!-- Slide 10: Conclusion -->
<section class="slide-background-content">
<h2>Conclusion: Preserflo™ in Modern Glaucoma Care</h2>
<div class="slide-content">
<div class="visual-content">
<i class="fas fa-graduation-cap"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Graphic representing innovation or forward-thinking]</p>
</div>
<div class="text-content pl-8">
<h3>Key Takeaways</h3>
<p>The Preserflo™ MicroShunt is an innovative surgical device offering a significant evolution in glaucoma treatment. [19]</p>
<ul>
<li>Provides effective and sustained IOP reduction, comparable to trabeculectomy in many cases, while reducing reliance on eye drops. [1, 12, 14, 17, 20]</li>
<li>Features an enhanced safety profile, notably lower rates of hypotony and potentially fewer overall complications compared to trabeculectomy. [1, 9, 19, 23, 28, 29]</li>
<li>Offers potential benefits of a less invasive procedure, faster recovery, and simpler post-operative management. [12, 19, 23, 25, 26]</li>
</ul>
<p>It represents a valuable and reliable option for surgeons and patients seeking effective IOP control with improved safety and predictability in the management of open-angle glaucoma. [1, 19, 22, 23]</p>
<span class="citation">Sources: [1], [9], [12], [14], [17], [19], [20], [22], [23], [25], [26], [28], [29]</span>
</div>
</div>
</section>
</div>
</div>
<!-- reveal.js -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/notes/notes.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/markdown/markdown.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/highlight/highlight.min.js"></script>
<script>
Reveal.initialize({
hash: true, // Enables deep linking to slides
plugins: [ RevealMarkdown, RevealHighlight, RevealNotes ] // Basic plugins
});
</script>
</body>
</html>